CTI Biopharma reported 917K in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Baxter International BAX:US $ 2289M 68M
Bristol Myers Squibb BMY:US $ 2677M 206M
CTI Biopharma CTIC:US 917K 639K
Eli Lilly And LLY:US $ 1430.5M 641.6M
Novartis NOVN:VX SF 3749M 6M
Novartis NVS:US $ 3749M 6M
Seattle Genetics SGEN:US $ 106.1M 18.47M
Teva Pharmaceutical Industries TEVA:US $ 1958M 99M
YTE INCY:US $ 45.24M 8.02M